Links
Lead indication: VTE prevention in cancer
Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI insight 2019;4.
Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2019.
Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI insight 2017;2:e89373.
Abu Saadeh F, Norris L, O’Toole S, Gleeson N. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):214-8.
Shafabakhsh R, Asemi Z Quercetin: a natural compound for ovarian cancer treatment. J Ovarian Res. 2019 Jun 15;12(1):55. doi: 10.1186/s13048-019-0530-4. Review.
Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-8.
Secondary Indication: Prevention of thrombosis in steady state sickle cell disease (SCD) patients as well as eventually prone to crisis SCD patients.
Maria A. Lizarralde-Iragorri 1 ∗, Bindu Parachalil Gopalan, et al. Isoquercetin for thromboinflammation in Sickle Cell Disease 2023/11 https://www.sciencedirect.com/science/article/pii/S2473952923006353
Muntjeeb M Syed 1, Pooja J Doshi 1, et al. Potential of isoquercitrin as antisickling agent: a multi-spectroscopic, thermophoresis and molecular modeling approach. DOI: 10.1080/07391102.2019.1645735
Pipeline indications
Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, Zhang H, Luo H, Zhu L, Jiang P, Chen L, Shen Y, Luo M, Zuo G, Hu J, Duan D, Nie Y, Shi X, Wang W, Han Y, Li T, Liu Y, Ding M, Deng H, Xu X. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol. 2004 Oct;78(20):11334-9.
Lili Chen et al. 2006. Binding interaction of quercetin-3-b-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features. Bioorganic & Medicinal Chemistry 14 (2006) 8295–83.
Khaerunnisa, S.; Kurniawan, H.; Awaluddin, R.; Suhartati, S.; Soetjipto, S. Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study. Preprints 2020, 2020030226 (doi: 0.20944/preprints202003.0226.v1).
Nguyen et al 2012. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol Lett 2012;34:831–8.